Piero Vernia

Piero Vernia

Auto-generated profile, based on publicly available information

Piero Vernia

Department of Internal Medicine and Medical Specialties, Gastroenterology, Sapienza University of Rome, Rome, Italy

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in Digestive and Liver Disease
Verified
Journal Article
Closed access
RDRiccardo Di Domenicantonio
Riccardo Di Domenicantonio
GCGiovanna Cappai
Giovanna Cappai
MAMassimo Arcà
Massimo Arcà
NANera Agabiti
Nera Agabiti
AKAnna Kohn
Anna Kohn
MDMarina Davoli
Marina Davoli

1 May 2019 in Digestive and Liver Disease
Verified
Journal Article
Closed access
GSGiorgia Burrelli Scotti
Giorgia Burrelli Scotti
MAMaria Teresa Afferri
Maria Teresa Afferri
ACAurora De Carolis
Aurora De Carolis
VVValentina Vaiarello
Valentina Vaiarello
VFValeria Fassino
Valeria Fassino
PVPiero Vernia
Piero Vernia

1 August 2007 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
EAErika Angelucci
Erika Angelucci
ACAndrea Cocco
Andrea Cocco
AVAngelo Viscido
Angelo Viscido
PVPiero Vernia
Piero Vernia
RCRenzo Caprilli
Renzo Caprilli

1 May 2019 in Digestive and Liver Disease
Verified
Journal Article
Open access
MSMaria Lia Scribano
Maria Lia Scribano
FCFlavio Andrea Caprioli
Flavio Andrea Caprioli
AMAndrea Michielan
Andrea Michielan
ACAntonella Contaldo
Antonella Contaldo
APAntonino Carlo Privitera
Antonino Carlo Privitera
AOAmbrogio Orlando
Ambrogio Orlando
The MARS-5 (Medication Adherence Report Scale) was developed in English. The aim of this project was to analyse the MARS-5I (© Prof Rob Horne) psychometric properties and to identify whether its Italian translation is suitable for assessing medication adherence in Crohn Disease (CD) Italian patients. The MARS was translated and linguistically validated in Italian. The MARS-5I was used for evaluating medication adherence in the SOLE study, conducted in Italy on 552 subjects with CD. In order to un-bias the questionnaire results from the effects of treatment change and/or effectiveness, the analyses were performed on the 277 patients whose disease activity remained stable, selected among the 371 patients who maintained the same treatment between two consecutive visits. Internal consistency was high (Cronbach's alpha of 0.86). Pearson's correlation coefficient was 0.50 (p<0.001) and 0.86 (p<0.001- outliers removed), indicating satisfactory test-retest. MARS 5I scores were not correlated with Treatment Satisfaction Questionnaire for Medication but a small and statistically significant correlation was shown with physician-evaluated medication adherence, indicating convergent validity. MARS-5I, the Italian translation of the English MARS, showed satisfactory internal consistency and test-retest, and a low but statistically significant convergent validity. We confirmed the utility of this tool in patients with CD.

1 February 2010 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
MCM. Cesarini
M. Cesarini
EAEmanuele Angelucci
Emanuele Angelucci
MRM. Rivera
M. Rivera
RProberta pica
roberta pica
PPP. Paoluzi
P. Paoluzi
ECE. S. Corazziari
E. S. Corazziari